Company / Current Assets
CRISPR Therapeutics AG Current Assets History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Assets
$2.0B
FY2025
5-year range
$1.9B / $2.4B
FY2021-FY2025
Trend
+2.5%
vs FY2024
Sector context
#32 of 215
Health Care
What the data says
CRISPR Therapeutics AG's current assets of $2.0B is higher than 85% of companies in the Health Care sector (FY2025). Current Assets has increased for 3 consecutive years, from $1.9B in FY2022 to $2.0B in FY2025.
Based on SEC 10-K filings.
$2.0B in FY2025 with a 5-year CAGR of +3.0%. Top quartile in the Health Care sector.
Improved from $1.9B to $2.0B over the past 2 years.
Health Care sector context is included.
Current Assets over time
Growth rates
- 3-Year CAGR
- +2.3%
- 5-Year CAGR
- +3.0%
- 10-Year CAGR
- -
Sector benchmark
Top 15% in Health CareTop 15% of 215This company $2.0B Sector average $2.5B
▼
-21.6% below sector average
Key checks
Key Insights
- CRISPR Therapeutics AG's current assets has grown for 3 consecutive years.
- 5-year CAGR of +3.0%, indicating consistent growth.
- In FY2025, current assets increased 2.5% year-over-year.
- Ranks #32 out of 215 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current AssetsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.0B | +2.5% |
| FY2024 | $1.9B | +1.5% |
| FY2023 | $1.9B | +3.0% |
| FY2022 | $1.9B | -23.3% |
| FY2021 | $2.4B | +40.8% |
| FY2020 | $1.7B | +73.8% |
| FY2019 | $987.5M | +111.7% |
| FY2018 | $466.4M | +87.8% |
| FY2017 | $248.4M | -22.4% |
| FY2016 | $320.2M | +104.1% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026